Abstract

Protein-based virus-like particles (P-VLPs) are commonly used to spatially organize antigens and enhance humoral immunity through multivalent antigen display. However, P-VLPs are thymus-dependent antigens that are themselves immunogenic and can induce B cell responses that may neutralize the platform. Here, we investigate thymus-independent DNA origami as an alternative material for multivalent antigen display using the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, the primary target of neutralizing antibody responses. Sequential immunization of mice with DNA-based VLPs (DNA-VLPs) elicits protective neutralizing antibodies to SARS-CoV-2 in a manner that depends on the valency of the antigen displayed and on T cell help. Importantly, the immune sera do not contain boosted, class-switched antibodies against the DNA scaffold, in contrast to P-VLPs that elicit strong B cell memory against both the target antigen and the scaffold. Thus, DNA-VLPs enhance target antigen immunogenicity without generating scaffold-directed immunity and thereby offer an important alternative material for particulate vaccine design.

Three-dimensional DNA origami constructs can be used to deliver vaccine antigens in a multi-valent form. Here the authors design a DNA origami system for SARS-CoV-2 proteins and characterize in mice the immune response and protective capacity of generated antibodies, finding that the construct itself is not immunogenic.

Details

Title
Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds
Author
Wamhoff, Eike-Christian 1 ; Ronsard, Larance 2   VIAFID ORCID Logo  ; Feldman, Jared 2 ; Knappe, Grant A. 3   VIAFID ORCID Logo  ; Hauser, Blake M. 2   VIAFID ORCID Logo  ; Romanov, Anna 4   VIAFID ORCID Logo  ; Case, James Brett 5   VIAFID ORCID Logo  ; Sanapala, Shilpa 5 ; Lam, Evan C. 2 ; Denis, Kerri J. St. 2   VIAFID ORCID Logo  ; Boucau, Julie 2   VIAFID ORCID Logo  ; Barczak, Amy K. 2   VIAFID ORCID Logo  ; Balazs, Alejandro B. 2   VIAFID ORCID Logo  ; Diamond, Michael S. 6   VIAFID ORCID Logo  ; Schmidt, Aaron G. 7   VIAFID ORCID Logo  ; Lingwood, Daniel 2   VIAFID ORCID Logo  ; Bathe, Mark 8   VIAFID ORCID Logo 

 Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Massachusetts Institute of Technology and Harvard University, Ragon Institute of Massachusetts General Hospital, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, Department of Chemical Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Washington University School of Medicine, Department of Medicine, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002) 
 Washington University School of Medicine, Department of Medicine, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University School of Medicine, Department of Molecular Microbiology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002) 
 Massachusetts Institute of Technology and Harvard University, Ragon Institute of Massachusetts General Hospital, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Harvard Medical School, Department of Microbiology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
Pages
795
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2919971003
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.